You are here

Cryopreservation of Engineered Tissue Equivalents

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 9R44GM106732-02A1
Agency Tracking Number: R44GM106732
Amount: $485,382.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: 300
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-26
Award End Date (Contract End Date): 2016-08-31
Small Business Information
2231 TECHNICAL PKWY, STE A, North Charleston, SC, 29406-4931
DUNS: 079664919
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 LIA CAMPBELL
 (843) 722-6756
 lcampbell@celltissuesystems.com
Business Contact
 KELVIN BROCKBANK
Phone: (843) 514-6164
Email: kgbrockbankassoc@aol.com
Research Institution
N/A
Abstract
DESCRIPTION provided by applicant In an effort to reduce the use of animals for toxicity testing companies have developed in vitro skin models or equivalents to replace the Draize skin irritation test This development has been further pushed by the European Union regulation that has prohibited the use of animals for collecting toxicological data on cosmetic ingredients that began Supply of these engineered tissues skin equivalents is a significant issue that can be solved by development of effective cryopreservation methods Presently these constructs are made to order and require a lead time of several weeks before they can be used A cryopreserved product would be available when needed eliminating lead time required to manufacture the product Additionally performance of quality control checks for stock that is ready to be shipped could be performed and large batches could be manufactured providing a cost savings to suppliers A cryopreserved skin model would also provide the end user greater flexibility for scheduling of experiments without concern regarding availability of the constructs and it would be possible to order from the same batch of product in order to have better control of uniformity within research studies In Phase I our alternate strategy vitrification was used t successfully cryopreserve the skin construct Epiderm with a viability of Three specific aims are proposed for Phase II The vitrification protocol will be optimized for epithelial tissue constructs in well inserts to include not only Epiderm but other epithelial tissue constructs relevant to toxicity testing In addition experiments are planned to scale up the vitrification process for larger numbers of samples and determine optimum storage and shipping conditions This optimized process would also be applicable to other tissue engineered tissue constructs such as cardiovascular tissue equivalents PUBLIC HEALTH RELEVANCE Tissue constructs like Epiderm have been developed by several companies to be used as in vitro replacements for the in vivo skin irritation and corrosivity tests A preservation method for these type of constructs for skin and other tissues will insure that these constructs are readily available when needed providing a less expensive consistent quality controlled product Success in this project will help reduce the number of animals employed for research reduce cost of tissue equivalent constructs and increase availability of human test models that may be more predictive of toxicity in humans than current live animal models

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government